OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-12-31-accounts

Company Number 06884476

YORK AGAINST CANCER

A company limited by guarantee and

A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended

31 December 2021

HPH Chartered Accountants 54 Bootham York YO30 7XZ

YORK AGAINST CANCER

CONTENTS
Page
Chairman’s Report 1
Trustees’ Report 2 ‐ 13
Auditor’s Report 14 – 17
Statement of Financial Activities 18
Balance Sheet 19
Cash Flow Statement 20
Notes to the Financial Statements 21 ‐ 31

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2021

2021 remained a challenging year with lockdowns continuing and numerous restrictions on personal liberty running throughout much of the year. As a result, much of our work was again affected, but as the months passed, we were at last getting back to something like normal.

It was a great tonic to see many of our volunteers as the year progressed, and as most of you will be much aware we have, at last, moved into our new premises at the Community Stadium.

Our small team continued to work hard throughout the year, and to them, our volunteers, and Board colleagues I would like to pass on my grateful thanks for continuing to promote the Charity during a really difficult period.

Work of course continued, and the need to strategically plan for our future requirements goes on to ensure we remain in a position to continue the important services for people touched by cancer – services that will be ever more important as we consolidate and expand on the outstanding work undertaken in the many areas that the Charity is involved in.

We sadly lost a number of our volunteers throughout the year, and our thoughts go out to their families, and we wish them well for the future. Every one of them supported the day to day work of the Charity, and helped the Charity to continue to provide the important services and funding for research that the we are recognised for.

Despite the ongoing restrictions, our minibus service continued to operate in difficult conditions, and special thanks go to drivers Ian and Neil for providing this vitally important service when many other cancer services were still curtailed by the NHS. Ian retired in May and subsequently welcomed Garry. Working in the office, promoting the Charity or driving our minibus our small and important band of dedicated staff are the daily face of York Against Cancer, and ably supported by our committed army of volunteers, the Charity remains in good hands.

A number of projects are under evaluation for the coming year, and I very much hope the Chair’s report for 2022 will be much more representative of the positive things the Charity is able to deliver.

Ian Yeowart Chair York Against Cancer

www.yorkagainstcancerorg.uk 1

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2021.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: ‐

Achievements and performance

SUPPORT ACTIVITIES

Support Team

The small team of hardworking office staff deal effectively with all aspects of the day‐to‐day operation of the charity, and it is worth noting that during 2021 there has been an inevitable impact on fundraising and charity/staff/board morale and the charity have striven to deal with those demands and risen to meet the challenges head on.

The relocation of the office and one of the retail outlets into the York Community Stadium was managed by the staff and was completed on the May 14th. As well as an increased amount of much needed space, the new environment facilitates opportunities to form new relationships with stakeholders.

The team’s work is sometimes challenging as they deal with people facing cancer and on occasions, this can impact on their resolve, however, they deal with this together and their teamwork is impressive. The team are friendly and often are found smiling. The way it is possible for our manager and her staff to respond quickly to any requests or challenges is a key strength for York Against Cancer as a local charity.

www.yorkagainstcancerorg.uk 2

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

SUPPORT ACTIVITIES

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients the time‐ consuming and tiring journeys to the hospital in York. During the Covid pandemic the MCU was repurposed and used as a standalone cancer department at the Scarborough hospital site.

Respite Properties

The Respite house in Filey continues to provide a welcome break; cancer patients and their families are offered either a three‐day weekend or four‐day weekday break. The many letters of appreciation we receive are an indication of how much a short break in the luxurious surroundings is appreciated.

During 2021 the YAC board decided to sell the Whitby apartment; the property had been popular however there were increasing problems with the upkeep of the property. The board, are looking into extending this service, in the near future, and are through exploring opportunities to buy an additional property.

Minibus

Our minibus service has also been affected by Covid, for a few months it was not able to run but as soon as the restrictions allowed it resume, however, with a restricted number of passengers. It continues to be an excellent and much‐valued service of transporting patients to St. James’ Hospital.

The thoughtful and kind approach of our minibus drivers has also again been very much appreciated.

www.yorkagainstcancerorg.uk 3

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

SUPPORT ACTIVITIES

Posts and services supported by York Against Cancer

In addition to the team directly employed by the charity there are other support workers whose salary costs are paid by York Against Cancer. These posts are itemised below and illustrate the range of activities supported by the Board:

Health Care Assistant

The Health Care Assistant continued to provide support for families affected by cancer until November 2021. These appointments are made in conjunction with the NHS to provide support for patients and their families; support which is not available through the normal NHS services.

Complementary Therapy

Complementary therapy arranged through the Cancer Care Centre has been significantly affected by Covid‐19 and patients have been offered complementary therapy and other services virtually until April 2021.

Clinical Research Nurse and Assistant posts at York Hospital

During the pandemic, some research nurses were still able to keep some Oncology Research going and three new studies were opened near the year end.

Health Welfare Advisor

The charity continues to support the Citizens Advice Bureau in their work with cancer patients at Scarborough hospital: this work provides support for those having cancer treatment and based at Scarborough to ensure that they receive all the help to which they are entitled.

All these supported positions are initially given for a fixed term (usually two or three years) and then reviewed by the Board. This is done to ensure that the money so generously raised by our supporters is used in the most efficient way.

The services have been hindered by the closure of the Cancer Care Centre at the hospital during the year. The charity committed to opening a new centre fully funded by the charity. The Leveson Centre is due to open in 2022 at the York Community Stadium. The Centre will offer a wide range of holistic cancer support services to complement the clinical treatments provided at York Hospital.

www.yorkagainstcancerorg.uk 4

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

RESEARCH ACTIVITIES

Jack Birch Unit (University of York)

The Charity is committed to another 3 years supporting the work of the Jack Birch Unit. The roles supported by York Against Cancer are: ‐

Director of the Jack Birch Unit

Assistant Director

Laboratory technician

Administrative assistant

Research Fellow in Informatics at the Jack Birch Unit is also being supported from 2019 to 2024.

Jack Birch Unit of Molecular Carcinogenesis

For the JBU, 2021 was a challenging year with limits on occupancy in the labs and constant changing of rules applied variously to staff and students. We faced some difficulties with obtaining laboratory supplies and our usual collection of surgical samples from our NHS colleagues took a big hit. Nevertheless, the JBU esprit de corps kicked in and the group worked together as a team, with weekly laboratory meetings and bimonthly lab management meetings held via zoom. Placement Masters and Undergraduate students, hoping for lab experience were most affected, as their projects became virtual. One third year BSc student, Sophie Curran worked with the YAC office on a successful science communications project looking at the use of Instagram to spread information to younger people about the risks and early signs of cancer.

We had a few staff changes. Richard Gawne joined Dr Andrew Mason’s group as a bioinformatician and Katie Skinner left to take up her PhD position in Atlanta. Ben Jarvis completed a Masters by Research and left to take up a PhD position in Manchester. Dr Sreemoti Banerjee moved to a postdoc job in Leeds and Dr Annu Joseph joined us as a postdoc on a new Wellcome LEAP grant on kidney engineering – part of a collaboration with colleagues at University College London and the Universities of Edinburgh and Manchester.

In October 2021, Simon Baker caught COVID in the delta wave, testing positive 48 hours before the most important interview of his career. So we are delighted to report that following his interview, Simon was awarded a prestigious Kidney Research UK fellowship to continue his work in the JBU. YAC funding has been critical to Simon’s work, which is investigating a childhood virus as the possible cause of bladder cancer and he could not have achieved any of this without YAC’s support.

www.yorkagainstcancerorg.uk 5

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

RESEARCH ACTIVITIES

One of the advantages with zoom is that we were able to participate in virtual workshops and meetings with international audiences. For a flavour of these, Dr Andrew Mason organised a very successful workshop on Disruptive ‘Omics Technologies in Molecular Medicine in March, and I chaired, and Dr Simon Baker presented at, sessions of the 3[rd] Bladder Cancer Translational Research Meeting in May. Between us, the JBU published eight scientific papers and one book chapter during 2021.

As the labs became more accessible in late 2021, Lauren and Hayley visited the JBU to take away some news stories to share with YAC. I am always delighted to show off our brilliant laboratories to visitors, so please do feel free to contact the YAC office or me directly, if you would like to arrange a visit.

I would like to thank York Against Cancer Board, fundraisers and supporters for the research support we receive. I also gratefully acknowledge the invaluable contribution that our scientific and clinical collaborators make to the quality and output of our research.

Professor Jenny Southgate, Director,

Jack Birch Unit of Molecular Carcinogenesis, University of York

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Education and Awareness Committee Report 2021.

Firstly, can I pass on my thanks to Stuart Parker (outgoing Chair) and the other members of the team who have continued to work hard despite the constraints of the Covid ‐19 pandemic. Our small but committed team has continued to meet via zoom this year.

The Enthuse partnership remained stalled due to the pandemic, but the funding will be rolled forward to a point in time when teachers are able to participate in the project. I hope we will have a positive update on this project in 2022.

After not being able to distribute sun hats and sun awareness leaflets into schools in 2020, we are pleased to announce that in 2021 this annual delivery restarted. Our committed volunteers help us with the distribution to the participating schools.

We held a cancer awareness day at Vanguard for the first time, this proved to be successful. The day helped launch the sale of our Christmas cards and drew attention to the relocation of the shop to the Community Stadium site. The committee recommended to the Board that we consider having two awareness day’s a year – one in the city centre and one at Vanguard/Community Stadium.

We have distributed 317 picture books to schools to support children who are affected by cancer. Thank you to the office and volunteers who supported this project and delivered books into local schools.

www.yorkagainstcancerorg.uk 6

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

EDUCATION ACTIVITIES

Stuart mentioned in his 2020 report that the committee had undertaken a brainstorming session, during 2021 we narrowed our ideas down! With Covid restricting our work with schools, the committee decided to look at how we could raise awareness in the community of signs and symptoms of cancers and the screening that is available. We wanted to focus our attention on underrepresented groups or cancers with poor screening uptakes. Unfortunately, it has taken longer to access this information than we anticipated so we have not made as much progress as we would all have liked.

In collaboration with the Communication committee, we have had preliminary discussions on how to achieve a physical as well as a digital presence across the whole YAC region.

Thank you to Julie and her team, as well as to committee members Stuart, Simon, Joan and Jane. We hope that 2022 will see an increase in our committee membership, that Enthuse takes off and we are able to put into action our plans for raising awareness as well as continuing our work with primary schools.

Lynn Bartram

Chair, Education and Awareness group

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity. With a sudden increase in legacies over the last few years the board established a Finance Sub‐group to consider the most effective way to manage the funds for the future of the charity. The Board has agreed with the recommendations of the sub‐group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long‐term plans and services the charity provides can be continued into the foreseeable future.

Future projects include: ‐

www.yorkagainstcancerorg.uk 7

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

FUNDRAISING

The retail outlets, at Huntington and the Hospital have continued to be an invaluable source of income and the hospital shop provides a very useful ‘shop front’ for the charity. The sterling work done by our volunteers; and our staff in the office has yet again given up many hours in the evening and at weekends to help raise funds and spread the message about York Against Cancer. The links with the local business community have again proved a great benefit to the charity. With all these efforts from our employed staff and volunteers the charity is able to provide more much‐needed support to many in the local community.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2021 in relation to its fundraising activities.

Fundraising report 2021

Following on from 2020, 2021 proved to be another tricky year for fundraising. We had some events planned that had to be postponed or just simply did not happen ‐ for example York Rocks Against Cancer. However, we did still have some larger fundraisers, such as the golf day and the Dragon Boat race, that did go ahead and were very successful. This year, we have been supported by Marks and Spencers Vangarde, Forest of Galtres golf club, Sainsburys Monks Cross, JWP Creers and Iceland at Clifton Moor.

Our supporters have done a fantastic job moving with the times and finding ways to fundraise even though we could not be together, something just as simple as a group of friends putting £1 away each week raised £370. We also benefitted from the Jack Birch Unit who launched a successful run/walk 50k in 10 days fundraiser for us while we were still locked down. The combination of our own events and support from the local people of York and the surrounding areas has meant that, although some momentum has been lost, York Against Cancer has been kept going through a really difficult time. We are so grateful to the people who take the time to raise money for us, we simply would not be here without their help.

Overall, we have managed to carry on where we can and adapt where necessary to make the most of the events, we have been able to hold. We have also been able to broaden our income stream by improving our online donating facilities as well as encouraging online donations and investing in tap to donate. We are so grateful to all our supporters who have continued their support through another tricky year. We are very much looking forward to a brighter year ahead.

Lauren Hudson

Head of Fundraising and Executive Assistant

www.yorkagainstcancerorg.uk 8

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision‐ making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day‐to‐day management of the affairs of the Charity to one Board member, Tarnia Hudson, who serves as the Honorary Administrator.

The members of staff employed by the Charity during the year were:

Julie Russell General Manager
Heather Atkinson Office & Accounts Manager
Lauren Hudson Personal Assistant to General Manager
Nicola Doherty Office & Volunteer coordinator
Helen Watkinson Retail Manager until 26thNovember 2021
Francine Clee PR & Communications Officer P/T until 14thMay 2021
Hayley Johnson Communications Manager P/T from 5thJuly 2021
Ian Stephenson Minibus Driver P/T until 25thMay 2021
Neil Johnson Minibus Driver P/T
Garry Stanton Minibus Driver P/T from 27thMay 2021

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a three‐year rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re‐elected for a further 3‐year term up to a maximum of 9 years in total (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the General Manager.

No Board member received any income or expenses for their work for the charity.

www.yorkagainstcancerorg.uk 9

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity’s two shops.

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects. The relocation to the York Community Stadium in May 2021 provides greater storage and office space and a retail outlet with a good footfall.

It should be emphasised that supporting staff not directly employed by York Against Cancer is always done on a time‐limited basis (typically two years) which is renewed as appropriate provided funds are available. The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and polices

The Charity’s funds in 2021 increased by £495,416. Large investment gains have further increased the surplus made. Prior to any adjustment for investments, the Charity made a surplus of £109,854 (2020 deficit of £146,787). The charity only generated a surplus in the year as the Mobile Chemotherapy Unit came in under budget in prior years and the excess commitment of £109,763 was released in the year. The future running costs of the unit will be cover by the remaining restricted fund.

The principal funding sources are fund‐raising, the trading shops, donations, and legacies. Gross income in 2021 amounted to £647,704 (2020 £389,859). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

£143,861 (2020 £163,187) was committed on project expenditure, to support the Charity’s ongoing projects. The already committed projects cash spend was a further £447,546.

Due to COVID‐19 there were limited additional projects taken on this year however two large projects not let confirmed at the year‐end have been since committed two since the year end. These are the Robotic Surgery and The Leveson Centre.

The detail of funding of projects can be found in note 6.

www.yorkagainstcancerorg.uk 10

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the ‘free reserves’ should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity’s funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2021. Funds not invested are held on deposit to earn interest.

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2021, before fees, was 10.99% (2020 0.43%). The total return on investment portfolio managed by Ruffer for the year ended 31 December 2021, before fees, was 11.80% (2020 11.88%).

Reserves Policy

The reserves policy is to generate a stable and sustainable return to fund grant making, to ensure continued financial security and to provide for contingencies. Cash reserves are accumulated before making a binding commitment to fund a project due to the nature and uncertainty of the income streams. The total funds held as at 31 December 2021 are £4,778,060 (2020 £4,282,644).

The Board is very mindful that the charity has a substantial reserve of funds at present after the receipt of some large legacies. The board is actively seeking to find effective ways in which these can be utilized to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Undesignated Fund

These are free reserves retained to provide working capital and funds for future projects. At the end of the financial year, the free reserves were £3,041,746 (2020 £3,503,531) accumulated largely due to the receipt of several generous legacies, which by their very nature are unpredictable. The level of free reserves will enable the Charity to give significant support to worthwhile projects which make a measurable impact.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £1,597,671 (2020 £635,088) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £138,643 (2020 £144,025) details of which are given in Note 17 to the financial statements.

COVID‐19 has had a significant impact on donations and fundraising since April 2020. The charity has significant reserves brought forward and these will be used to help support the charity adapt where needed and keep its on‐going commitments.

www.yorkagainstcancerorg.uk 11

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors’ and Trustees’ responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company’s state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

Approved by the Board on 22 September 2022 and signed on its behalf by:

Ian Yeowart Director and Trustee

www.yorkagainstcancerorg.uk 12

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

Reference and administrative details

Registered Charity number 1130835 Company Limited number 06884476 by Guarantee

Principal Office and Trading Address

East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF

Company Secretary Julie Pamela Russell Directors and Trustees Andrew Proctor Dr Lynn Bartram Angela Darby Michael Sweet Rachel Goddard Robert Onyett Michael John Stower Tarnia Hudson William Mark Sessions Prof Stephen Leveson Ian Yeowart Michael Patrick Shepherd Sarah Wearing

Trustee’s protocol available on request

Accountants HPH Auditors Hentons & Co LLP Chartered Accountants Chartered Accountants 54 Bootham 124 Acomb Road York Holgate YO30 7XZ York YO24 4EY Bankers National Westminster Bank Solicitors Harrowells 1 Market Street Moorgate House York Clifton Moorgate YO1 8SR York YO30 4WY Investment Advisors HSBC Global Asset Ruffer LLP Management 80 Victoria Street 78 St James’s Street London London SW1E 5JL SW1A 1EJ

www.yorkagainstcancerorg.uk 13

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2021

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the ‘group’) for the year ended 31 December 2021 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

www.yorkagainstcancerorg.uk 14

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2021

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

www.yorkagainstcancerorg.uk 15

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2021

Irregularities, including fraud, are instances of non‐compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

www.yorkagainstcancerorg.uk 16

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2021

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

………………………………………………..

Brett Davis (Senior Statutory Auditor)

For and on behalf of Hentons

Chartered Accountants

Statutory Auditor

124 Acomb Road York YO24 4EY

Date: 22 September 2022

www.yorkagainstcancerorg.uk 17

YORK AGAINST CANCER

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2021

Note
Income and endowments from:
Donations and legacies
2
Other trading activities
3
Investments
4
Total
Expenditure on:
Raising funds
5
Charitable activities
6
Total
Net income/(expenditure)
before gains on investments
Net gains on investments
11
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
403,515
-
199,087
-
45,102
-
647,704
-
199,970
-
325,394
7,104
525,364
7,104
122,340
(7,104)
385,562
-
507,902
(7,104)
(969,687)
969,687
(461,785)
962,583
3,503,531
635,088
3,041,746
£
1,597,671
£
Unrestricted		 Restricted
Funds
£
-
-
-
-
-
5,382
5,382
(5,382)
-
(5,382)
-
(5,382)
144,025
138,643
£		 Year ended
31 Dec
2021
£
403,515
199,087
45,102
647,704
199,970
337,880
537,850
109,854
385,562
495,416
-
495,416
4,282,644
4,778,060
£		 Year ended
31 Dec
2020
£
182,705
157,863
49,291
389,859
181,336
355,310
536,646
(146,787)
171,077
24,290
-
24,290
4,258,354
4,282,644
£

The notes on pages 21 to 31 form part of these financial statements.

18

YORK AGAINST CANCER (Registration number: 06884476)

BALANCE SHEET AS AT 31 DECEMBER 2021

FIXED ASSETS
Tangible Fixed Assets
12
Investments
11
CURRENT ASSETS
Stock
Debtors
13
Cash at Bank and in Hand
CREDITORS: amounts falling due
within one year
14
TOTAL ASSETS LESS CURRENT
LIABILITIES
CREDITORS: amounts falling due
after one year
15
NET ASSETS
THE FUNDS OF THE CHARITY
Unrestricted
Undesignated
18
Designated
16,18
Restricted
17,18
TOTAL CHARITY FUNDS
NET CURRENT ASSETS
Note		 Charity
2021
£
362,264
4,076,185
4,438,449
-
540,858
819,603
1,360,461
498,519
861,942
5,300,391
537,202
£ 4,763,189
3,069,782
1,554,764
138,643
£ 4,763,189		 Consolidated
2021
£
405,171
4,076,184
4,481,355
55,176
449,771
846,463
1,351,410
517,503
833,907
5,315,262
537,202
£ 4,778,060
3,041,746
1,597,671
138,643
4,778,060
£		 Charity
2020
£
573,526
3,741,011
4,314,537
-
551,936
827,681
1,379,617
487,559
892,058
5,206,595
961,016
£ 4,245,579
3,478,282
623,272
144,025
£ 4,245,579		 Consolidated
2020
£
585,342
3,741,010
4,326,352
55,295
462,285
898,835
1,416,415
499,107
917,308
5,243,660
961,016
£ 4,282,644
3,503,531
635,088
144,025
£ 4,282,644

Approved by the Trustees on 21 September 2022 and signed on its behalf by:

S B Wearing Director and Trustee

The notes on pages 21 to 31 form part of these financial statements.

19

YORK AGAINST CANCER CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2021

Note
Cash flows from operating activities:
Net cash used in operating activities
21
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of property, plant and equipment
Proceeds from sale of property
Proceeds from sales of investments
Purchase of investments
Net cash provided by investing activities
Change in cash and cash equivalents in the
reporting period
Cash and cash equivalents at the beginning of
the reporting period
Cash and cash equivalents at the end of
the reporting period		 2021
£
(335,263)
45,102
(64,330)
251,731
1,838,749
(1,788,361)
282,891
(52,372)
898,835
£ 846,463		 2020
£
(363,320)
49,291
(2,990)
-
1,095,488
(1,117,345)
24,444
(338,876)
1,237,711
£ 898,835

The notes on pages 21 to 31 form part of these financial statements.

20

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The cash and investments held are sufficient to see the Charitable Company through the financial impact of COVID-19. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

21

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property at straight line over 50 years Equipment - Shop and office equipment at straight line over 10 years - Computer equipment at straight line over 3 years - Respite home equipment at straight line over 4 years - Motor vehicles at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2021. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

Government grants

These government grants relate to the COVID grants for retail closures issued to the subsidiary trading company.

22

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

2.
DONATIONS AND LEGACIES
In Memoriam
Legacies
Government grant
Intangible income
Donations		 Unrestricted
Restricted
2021
£
£
£
158,533
-
158,533
19,852
-
19,852
206,699
-
206,699
13,431
-
13,431
5,000
-
5,000
£ 403,515
£ -
£ 403,515		 2020
£
118,189
24,957
13,225
21,334
5,000
£ 182,705

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3.
OTHER TRADING ACTIVITIES
Fundraising income
Subsidiary's non-charitable trading turnover
4.
INVESTMENTS
Interest received
Dividends received
5.
ANALYSIS OF RAISING FUNDS
Advertising
Fundraising costs
Non charitable trading - other costs
Non charitable trading - staff costs
Non charitable trading - depreciation
Investment fees		 Unrestricted
Restricted
£
£
11,292
-
36,933
-
110,546
-
21,123
-
5,156
-
14,920
-		 2021
£
99,601
99,486
£ 199,087
2021
£
627
44,475
£ 45,102
2021
£
11,292
36,933
110,546
21,123
5,156
14,920
£ 199,970		 2020
£
72,639
85,224
£ 157,863
2020
£
2,696
46,595
£ 49,291
2020
£
7,900
65,847
70,995
22,165
2,515
11,914
£ 199,970
£ -		 £ 181,336

23

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

6. ANALYSIS OF CHARITABLE ACTIVITES

Direct project costs:
Research
Clinical Trial Nurses
Support and Care
Cancer Care Centre - Old
Complementary therapy
Health Care Assistant
Respite property expenses
Minibus running costs - direct
Mobile Chemotherapy Unit
Psychology services
Restricted grants
Health Welfare Advisor
Education
Education expenses
Support costs:
Staff costs
Staff training and travel
Rent, service charge and rates
Heat and light
Repairs and maintenance
Insurances
Printing, stationery and postage
Computer expenses
Telephone
Sundry expenses
Gains and losses on fixed assets
Depreciation
Governance costs:
Audit fees
Accountancy fees
Legal fees
Bank charges
Total charitable activities
Minibus running costs - staff costs
During the year the underspend on the Mobile Chemotherapy Unit wa
costs are covered by the restricted funds.		 Unrestricted
Restricted
2021
2020
£
£
£
£
95,051
-
95,051
19,239
6,511
-
6,511
26,330
-
-
-
29,541
12,818
-
12,818
7,865
21,103
-
21,103
29,257
12,248
-
12,248
7,029
20,439
-
20,439
18,533
(109,763)
5,382
(104,381)
321
4,040
-
4,040
5,680
-
-
-
12,222
73,444
-
73,444
-
2,588
-
2,588
7,170
138,479
5,382
143,861
163,187
139,079
-
139,079
134,916
2,553
-
2,553
1,702
21,779
-
21,779
4,352
1,837
-
1,837
1,666
173
-
173
1,932
3,416
-
3,416
2,963
4,870
-
4,870
4,856
7,819
-
7,819
7,867
2,693
-
2,693
1,710
6,384
-
6,384
3,953
(28,554)
-
(28,554)
-
16,168
-
16,168
13,500
178,217
-
178,217
179,417
4,560
-
4,560
3,480
7,507
-
7,507
7,663
2,182
-
2,182
-
1,553
-
1,553
1,563
15,802
-
15,802
12,706
£ 332,498
£ 5,382
£ 337,880
£ 355,310
s released as the project cost less than intially budgeted. Running		 2020
£
19,239
26,330
29,541
7,865
29,257
7,029
18,533
321
5,680
12,222
-
7,170
163,187
179,417
3,480
7,663
-
1,563
12,706
£ 355,310

24

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

7. NET INCOMING RESOURCES FOR THE YEAR
NET INCOMING RESOURCES FOR THE YEAR 2021 2020
£ £
This is stated after charging:
Depreciation 21,324 18,530
Auditor's remuneration for audit services - charity 4,560 3,480

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS

AFF COSTS
Wages and salaries
Social security costs
Pension costs
Medical Insurance		 2021
£
160,955
8,614
6,701
4,371
£ 180,641		 2020
£
155,368
8,710
7,104
4,432
£ 175,614

The average monthly head count was 8 staff (2020 8) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

d part-time staff) during the year were as follows:
Projects 1 1
Trading 1 1
Management and administration 6 6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees and the General Manager. The total employee benefits of the key management personnel of the Charitable Company were £50,303 (2020 - £49,937).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £92,808 (2020 £95,637). Interest of £186 (2020 £141) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

ummary of the results of the subsidiary is shown below:
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Other operating income
Interest payable
Profit on ordinary activities before taxation
Taxation
Profit on ordinary activities after taxation
Amount gifted to York Against Cancer
Retained (withdrawn from)/within Subsidiary
Net Assets		 2021
£
99,486
(64,071)
35,415
(72,754)
(37,339)
15,333
(186)
(22,192)
-
(22,192)
-
£ (22,192)
£ 14,871		 2020
£
85,224
(46,891)
38,333
(48,953)
(10,620)
11,334
(141)
573
-
573
-
£ 573
£ 37,063

25

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

11. INVESTMENTS

ESTMENTS
Consolidated
Market value at 1 January 2021
Additions at cost
Disposals
Revaluations
Market value at 31 December 2021
Analysis of investments by class:
Listed investments
The historical cost of the above investments amounts to:		 2021
£
3,741,010
1,788,361
(1,838,749)
385,562
£ 4,076,184
£ 4,076,184
£ 3,633,156		 2020
£
3,548,076
1,117,345
(1,095,488)
171,077
£ 3,741,010
£ 3,741,010
£ 3,521,243

The following material investments are over 5% by value of the investments held

HSBC FTSE All Share Index
Ruffer Charity Assets Trust Account		 2021
Market value
£
-
2,231,923
£ 2,231,923		 2020
Market value
£
302,095
2,010,192
£ 2,312,287

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

12. TANGIBLE FIXED ASSETS

TANGIBLE FIXED ASSETS
At 1 January 2021
Cost
Additions in year
Disposals in year
At 31 December 2021
At 31 December 2021
Depreciation
At 31 December 2020
At 1 January 2021
Charge for year
Disposals in year
At 31 December 2021
Net book value		 Subsidiary -
Motor
Charity
Shop
Property
Vehicles
Equipment
Total
Equipment
£
£
£
£
£
635,602
41,515
46,469
723,586
34,871
-
-
27,943
27,943
36,387
(267,900)
-
(34,079)
(301,979)
(19,697)
367,702
41,515
40,333
449,550
51,561
72,727
35,951
41,382
150,060
23,055
10,033
1,391
4,744
16,168
5,156
(45,989)
-
(32,953)
(78,942)
(19,557)
36,771
37,342
13,173
87,286
8,654
£ 330,931
£ 4,173
£ 27,160
£ 362,264
£ 42,907
£ 562,875
£ 5,564
£ 5,087
£ 573,526
£ 11,816		 Consolidated
Total
£
758,457
64,330
(321,676)
501,111
173,115
21,324
(98,499)
95,940
£ 405,171
£ 585,342

All fixed assets are held for direct charitable purposes in Designated Funds.

26

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

13.
Amounts owed by subsidiary
Prepayments
Accrued income
Other debtors
14. CREDITORS: amounts falling due
within one year
Trade creditors
Project creditors
Taxation and social security
Accruals
Other creditors
15. CREDITORS: amounts falling due
after one year
Project creditors
DEBTORS		 Charity
Consolidated
Charity
Consolidated
2021
2021
2020
2020
£
£
£
£
92,809
-
95,637
-
6,488
6,596
9,250
13,902
430,000
430,000
446,909
448,243
11,561
13,175
140
140
£ 540,858
£ 449,771
£ 551,936
£ 462,285
2,445 3,488 30,378 33,524
476,711
476,711 444,038
444,038
3,146
6,325 3,128
8,730
14,187
28,949 8,893
11,693
2,030
2,030
1,122
1,122
£ 498,519
£ 517,503
£ 487,559
£ 499,107
£ 537,202
£ 537,202
£ 961,016
£ 961,016

16.[DESIGNATED FUNDS (consolidated)]

The Charitable Company transfers to designated funds sufficient resources to meet such commitments, as shown below.

Designated Funds - 2021
Cancer Care Centre
Cancer Care Centre - New Centre
Complementary Therapy
Education Project
Minibus
Patient Travel
Robotic Surgery Project
Fixed Assets Fund
Total
Designated Funds - 2020
Cancer Care Centre
Complementary Therapy
Education Project
Minibus
Patient Travel
Fixed Assets
Total		 Balance
Income
Expenditure
Transfers
Balance
01/01/2021
31/12/2021
£
£
£
£
£
5,382
-
(5,382)
-
-
-
-
-
466,500
466,500
6,364
-
(6,364)
-
-
-
-
(2,588)
2,588
-
28,000
-
-
8,000
36,000
10,000
-
-
-
10,000
-
-
-
680,000
680,000
585,342
-
7,230
(187,401)
405,171
£ 635,088
£ -
£ (7,104)
£ 969,687
£ 1,597,671
Balance
Income
Expenditure
Transfers
Balance
01/01/2020
31/12/2020
£
£
£
£
£
31,500
-
(26,118)
-
5,382
35,480
-
(29,116)
-
6,364
-
-
(7,170)
7,170
-
-
-
-
28,000
28,000
-
-
-
10,000
10,000
600,882
-
(18,530)
2,990
585,342
£ 667,862
£ -
£ (80,934)
£ 48,160
£ 635,088

Cancer Care Centre

The Board is committed to a service level agreement with York Hospital to provide the funding for 3 administrator posts from 1 April 2019 to 31 March 2021.

27

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

16.[DESIGNATED FUNDS (consolidated continued)]

Cancer Care Centre - New Centre

The charity has set aside an initial budget for the provision of a new cancer care centre to be spent over the next year.

Complementary Therapy

The Board is committed to a service level agreement with York Hospital to provide the funding for a therapist post from 1 April 2019 to 31 March 2021.

Minibus

The trustees have set aside monies for the purchase of a new minibus which will be purchased next year.

Patient Travel

The trustees have set aside monies to fund Patient Travel and this will be reviewed next year once demand is known.

Robotic Surgery Project

During the year the charity started conversations with the NHS regarding supporting the Robotic Surgery facilities. Since the year end a formal commitment was made of £680,000.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

17. RESTRICTED FUNDS (consolidated)

TRICTED FUNDS (consolidated)
Restricted Funds - 2021
Mobile Chemotherapy Unit
Mouth Cancer
Total 2021
Restricted Funds - 2020
Mobile Chemotherapy Unit
Prostate Cancer
Mouth Cancer
Total 2020		 Balance
Income
Expenditure
Transfers
Balance
01/01/2021
31/12/2021
£
£
£
£
£
142,348
-
(5,382)
-
136,966
1,677
-
-
-
1,677
£ 144,025
£ -
(£ 5,382)
£ -
£ 138,643
Balance
Income
Expenditure
Transfers
Balance
01/01/2020
31/12/2020
£
£
£
£
£
142,069
600
(321)
-
142,348
12,222
-
(12,222)
-
-
1,677
-
-
-
1,677
£ 155,968
£ 600
(£ 12,543)
£ -
£ 144,025

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Prostate Cancer

50% of the R U taking the P monies raised where to be allocated to prostate cancer research.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

28

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2021
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Fund balances at 31 December 2020
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities		 General
Designated
Restricted
Total
Funds
Funds
Funds
2021
£
£
£
£
-
405,171
-
405,171
3,396,184
680,000
-
4,076,184
700,267
512,500
138,643
1,351,410
(517,503)
-
-
(517,503)
(537,202)
-
-
(537,202)
£ 3,041,746
£ 1,597,671
£ 138,643
£ 4,778,060
General
Designated
Restricted
Total
Funds
Funds
Funds
2020
£
£
£
£
-
585,342
-
585,342
3,741,010
-
-
3,741,010
1,222,644
49,746
144,025
1,416,415
(499,107)
-
-
(499,107)
(961,016)
-
-
(961,016)
£ 3,503,531
£ 635,088
£ 144,025
£ 4,282,644

19. OPERATING LEASE COMMITMENTS

As at 31 December 2021 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

for each of the following period:
At 31 December 2021 At 31 December 2020
Land and Office Land and Office
buildings equipment buildings equipment
Total operating leases payable: £ £ £ £
Within one year 40,298 - 15,000 -
Between two and five years 127,610 - - -

20. RELATED PARTIES

During the year the Charitable Company paid £2,829 (2020 £2,620) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £107 (2020 £nil) owing to HPH Chartered Accountants.

During the year the Charitable Company paid £2,160 (2020 £nil) to Harrowells Solicitors for legal fees, a firm in which the Charitable Company's Directorr, Robert Onyett, is a director.

During the year the wife of a director Ian Yeowart was paid £1,300 for temporary employment cover.

29

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

21. CASH FLOW NOTES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation charges
Gains on sale of fixed assets
(Gains)/Losses on investments
Dividends, interest and rents from investments
Increase in stocks
Increase in debtors
(Increase)/Decrease in creditors
Net cash used in operating activities
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash at bank and in hand
Total cash and cash equivalents
ANALYSIS OF CHANGES IN NET DEBT
At
01/01/2021
£
Cash
898,835
RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES		 2021
2020
£
£
495,416
24,290
21,324
18,530
(28,554)
-
(385,562)
(171,077)
(45,102)
(49,291)
119
1,964
12,514
232,045
(405,418)
(419,781)
£ (335,263)
£ (363,320)
846,463
898,835
£ 846,463
£ 898,835
At
Cash-flows
31/12/2021
£
£
(52,372)
846,463

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

30

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

24. COMPARATIVE INFORMATION

Income and endowments from:
Donations and legacies
Other trading activities
Investments
Total
Expenditure on:
Raising funds
Charitable activities
Total
Net expenditure
before losses on investments
Net gains on investments
Net income/(expenditure)
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
182,105
-
157,863
-
49,291
-
389,259
-
181,336
-
261,833
80,934
443,169
80,934
(53,910)
(80,934)
171,077
-
117,167
(80,934)
(48,160)
48,160
69,007
(32,774)
3,434,524
667,862
£ 3,503,531
£ 635,088
Unrestricted		 Restricted
Funds
£
600
-
-
600
-
12,543
12,543
(11,943)
-
(11,943)
-
(11,943)
155,968
£ 144,025		 Year ended
31 Dec
2020
£
182,705
157,863
49,291
389,859
181,336
355,310
536,646
(146,787)
171,077
24,290
-
24,290
4,258,354
£ 4,282,644

31